

Date: 5th February, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter and nine months ended 31st December, 2025.

With reference to the captioned subject, please find enclosed herewith Press Release on the Unaudited Financial Results for the quarter and nine months ended 31st December, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Press Release

Alembic Pharmaceuticals Ltd announces financial results for Q3 FY26

Q3 FY26 Revenue growth of 11%

Vadodara, February 5th, 2026

Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter and nine months ended 31st December 2025.

Financial Highlights for Q3FY26

- Revenue from operations increased by 11% to Rs.1,876 Cr.
- EBITDA increased by 14% to Rs. 308 Cr
- EBITDA Margin at 16% of revenue
- Profit Before Exceptional Items and Tax increased by 15% to Rs 205 Cr
- Pursuant to changes under the new labour code, the Company has recognised a one-time provision of Rs 42 Cr towards employee benefits.
- Reported Profit After Tax after this one-time provision was at Rs.133 Cr.

Commenting on the results, Mr. Pranav Amin MD, Alembic Pharmaceuticals Limited, said, *Our Q3 performance underscores the sustained momentum across our businesses supported by consistent execution, continued focus on profitability and operating rhythm. We further strengthened our presence in Australia, Canada, Europe, the USA and other key markets delivering an overall growth of 11%. Our pre-R&D EBITDA margin at 25% remains healthy. We continued to invest around 9% of revenue in R&D to build a robust pipeline for future growth. The integration of Utility Therapeutics progressed well, and we are working towards launch of Pivya™ in quarter 4 positioning us to expand our footprint in branded drugs in the US and create new avenues for sustainable growth.*

Operational Highlights

India Branded Business

- India Branded Business delivered a 6% YoY growth, reaching Rs 652 Cr. in revenue for the quarter.
- Gynaecology, Ophthalmology and Animal healthcare segments supported the growth for the quarter.

ALEMBIC PHARMACEUTICALS LIMITED

- Anti-infective segment grew in line with market performance.
- Successfully introduced 4 new products during the quarter.

International Business

- US Generics grew by 6% to Rs. 553 Cr. for the quarter.
- 2 Launches in the US market during the quarter.
- Ex-US International Generics grew by 36% to Rs. 406 Cr. for the quarter.
- 7 ANDA approvals received during the quarter, 232 Cumulative ANDA approvals.

API Business

- API business grew by 2% to Rs. 264 Cr. for the quarter.

The summary of Revenue from Operations is as under:

				(Rs in Cr.)		
Particulars	Q3 FY25	Q3 FY26	% Change	9M FY26	9M FY25	% Change
Formulation						
India	614	652	6%	1890	1795	5%
USA	521	553	6%	1642	1449	13%
Ex- US	299	406	36%	1126	868	30%
API	259	264	2%	839	791	6%
Total	1,693	1,876	11%	5,497	4,902	12%

Earnings Call: Alembic Pharmaceuticals Limited will host an investor call at 4:30 pm IST on February 5, 2026, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1411/ +91 22 7115 8312. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.alembicpharmaceuticals.com. The operator will provide instructions on asking questions before the start of the call.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information, contact:

Ajay Kumar Desai: Phone: +91 022- 66953681 Email: ajay.desai@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123